Vet Peptide Suppliers via Publication Footprints: Jagorar Ƙididdigewa

Tarkon Cigaban Bugawa: Me yasa ambaton Binary ya ƙidaya gazawar tantancewar sayayya

Ƙimar masu samar da peptide na al'ada ta hanyar jimlar ƙarar magana kawai yana haifar da amincewar ƙarya. A cikin wallafe-wallafen ilimi da masana'antu, ambaton reagent sun bambanta sosai a cikin fayyace, zurfin fasaha, da kuma tabbatar da matakin tsari.

Misali, takarda mai bayyanawa "An samo peptides daga Vendor X" yana ba da kusan babu hangen nesa mai aiki don ƙungiyar haɓaka tsarin biopharma. Yana barin tambayoyi masu mahimmancin aiki marasa amsa:

• An haɗa peptide na musamman don yin oda, ko ba da oda daga rukunin kasida da aka riga aka haɗa?

• Shin marubutan sun tabbatar da jerin sunayen, tsarki, da gishiri counterions a nasu dakin gwaje-gwaje, ko sun yarda da ƙayyadaddun dillalai a ƙimar fuska?

• Peptide Synthesis Shin gwajin ya ƙunshi yin afuwa in vitro dauri tantancewa, ko mai matuƙar hankali mai rai nazarin pharmacokinetic inda ragowar trifluoroacetic acid (TFA) ko endotoxins zai ɓata karatun nazarin halittu?

A cewar hukumar Jagoran EMA akan Haɓaka da Haɓaka na Peptides (2022), Hukumomin da ke da tsari suna sa ran samun cikakken tsarin samar da kayayyaki, cikakken sarrafa tsarin sarrafawa, da cikakken halayyar farawa kayan da m reagents. Hakazalika, da Jagorar Tabbatar da Hanyar Bioanalytical FDA (2020) ya jaddada cewa daidaito-zuwa-yawa da kuma cikakkiyar sifa mai mahimmanci na reagents suna da mahimmanci don rashin ƙarfi da kuma bin ka'idoji..

Don gina ingantacciyar hanyar tantance masu kaya, ƙungiyoyin masu samowa dole ne su wuce tsayin daka na binary da Peptides na roba kimanta da inganci, granularity, da kuma dacewa da aikace-aikacen na wallafe-wallafen da aka buga.

Samfurin Makin Ƙididdigar Ƙididdigar Ƙididdigar Ma'auni 4-Metric

Don canza bayanan ƙididdiga masu inganci zuwa madaidaicin matrix yanke shawara, sayayya da R&Ƙungiyoyin D za su iya ƙididdige abin da aka haɗa Makin Amincewar Mai siyarwa (VCS).

Ƙididdigar haɗaɗɗiyar ma'auni tana daidaita ganuwa wallafe-wallafe, hanyoyin sashe bayyana gaskiya, nazarin halittu aikace-aikace jeri, da danyen tantance bayanan tantancewa:

VCS = 0.25 × PCS + 0.25 × MRI + 0.25 × AAI + 0.25 × CQS

Kowane bangare yana wakiltar ma'auni na daidaitacce daga 0 ku 100, kimantawa da takamaiman sinadarai da ka'idojin adabi.

MAKIYAR TSARO MAI SALLA (VCS) VCS = 0.25(PCS) + 0.25(MRI) + 0.25(AAI) + 0.25(CQS)

1. Cigaban Bugawa | 2. Hanyoyi Rigor | 3. Daidaita Aikace-aikacen | 4. Makin Makin Ingantaccen CoA (PCS) | Fihirisa (MRI) | Fihirisa (AAI) | (CQS)

• Farashin JIF | * An Bayyana Jeri | * In vitro Screening (50) | * HPLC Haɗin kai

• Gudun Bugawa | * Ma'auni na Synthesis | * A cikin vivo / Dabba (75) | * Bayanin HRMS

• Independence Marubuci | * Lutu / Batch Lamba | * Tsarin tsari / NMR (90) | * Ƙaddamarwa / TFA

• Tutocin haɗin gwiwa | * Raw RP-HPLC/MS Hujja | * GMP / IND Pilot (100) | * Gwajin LAL Endotoxin

1. Makin Cigaban Bugawa (PCS)

The Makin Cigaban Bugawa (PCS) yana auna nauyin ƙididdiga da ikon kimiyya na ƙungiyar wallafe-wallafen da ke nuna mai bayarwa. Yana hukunta kai ambato, rubuce-rubucen haɗin gwiwa, da kuma ƙananan mujallu na cin zarafi yayin da ake ba da lada mai zaman kanta na nazarin nazari na ɗan adam a cikin mujallolin biopharma mai tasiri..

PCS = jimla_{i=1}^{n} ( JIF_i × Nauyi Na Kwanan baya )

• Factor Tasirin Jarida (JIF) Yin nauyi: Takardun da aka buga a cikin mujallun da aka bita tare da JIF > 5.0 (misali, Jaridar Magungunan Chemistry, Halittar Halittar Halittar Halitta, Nazari Chemistry) sami matsakaicin nauyi na asali.

• Nauyin Kwanan baya: Bugawa daga ƙarshe 36 watanni suna nauyi a 1.0; ambato ya girmi 5 shekaru suna rangwame zuwa 0.5 don yin la'akari da yuwuwar canje-canje a cikin kayan haɗin gwiwar mai siyarwa ko ma'aikata.

• Factor Independence: Littattafan ilimi masu zaman kansu ko ƙungiyoyin bincike na biopharma suka rubuta sun sami wani abu 1.0. Takardun da ma'aikatan dillalai suka rubuta tare suna karɓar kashi ɗaya 0.3 don daidaitawa don son zuciya na talla na ciki.

2. Hanyoyi Rigor Index (MRI)

The Hanyoyi Rigor Index (MRI) yana ƙididdige adadin dalla-dalla na fasaha da marubutan suka bayyana game da haɗin peptide, tsarkakewa, da gano kuri'a a cikin sassan gwaji da aka buga.

Hanyoyi mafi girma granularity suna da alaƙa da ƙarfi tare da bayyana gaskiyar mai siyarwa da sake fasalin tsari.

Key Takeaway: Dillali wanda takaddun da aka ambata a kai a kai sun haɗa da gyare-gyare a bayyane, yanayin kira, lambobi masu yawa, kuma chromatogram na nazari yana nuna babban girma na masana'antu fiye da wanda ambatonsa ya ƙunshi nau'ikan nau'ikan nau'ikan kawai..

Hanyoyi Sashe na Sharuɗɗa da aka Bayyana	Ma'ana darajar	Muhimmancin Kimiyya
Madaidaicin Jeri & Tashar Tasha	15 maki	Yana bayyana gyare-gyaren N-terminal/C-terminal (misali, Ac-, -NH2, PEGylation, fluorophore).
Mai sayarwa & Kasar Mai Suna	15 maki	Yana tabbatar da ainihin rabon haɗin kai maimakon sake siyar da gida na ɓangare na uku.
Ƙayyadaddun Hanyar Magana	20 maki	Yana ƙayyade SPPS (Fmoc/tBu vs. Boc/Bzl), ruwa-lokaci, ko hanyar enzymatic/fermentation.
Matsayin Tsabta & Hanyar HPLC ta bayyana	20 maki	Cites manufa tsarki (misali, ≥95%, ≥98%) tare da ginshiƙi na nazari da sigogin gradient.
Batch / An Bayyana Lambar Lamba	15 maki	Yana ba da alaƙa da za a iya ganowa tsakanin bayanan nazarin halittu da aka buga da takamaiman tsari na samarwa.
Raw Analytical Data Haɗe	15 maki	Ya haɗa da ƙarin RP-HPLC chromatograms ko yawan bakan (ESI-MS/HRMS).

3. Fihirisar Daidaita Aikace-aikace (AAI)

The Fihirisar Daidaita Aikace-aikace (AAI) yana kimanta ko wallafe-wallafen mai siyarwa ya dace da rikitaccen aiki na takamaiman bincikenku ko shirin haɓaka magunguna.

Mai kaya da 100 ambato a takaice, peptides na layi na antigenic da aka yi amfani da su a cikin ƙididdigar ELISA na asali na iya ƙima mara kyau idan aka kimanta su don hadadden sunadarai na peptide..

• Mataki 1: Basic In Vitro Assays (Ci: 50/100) - Katange yamma, polyclonal antibody tsara, ELISAs na yau da kullun.

• Mataki 2: Al'adun Kwayoyin Halitta & Nau'in Nuni Mai Girma (Ci: 75/100) - peptides masu shiga cikin kwayar halitta, aikin rabe-raben agonism/antagonism, organoid toxicity screening yana buƙatar tabbatar da ƙananan matakan endotoxin.

• Mataki 3: Tsarin Halittu & A cikin Nazarin Vivo (Ci: 90/100) - Cyo-EM, X-ray crystallography, NMR, PK/PD, Gwajin kwanciyar hankali yana buƙatar madaidaicin musayar TFA-to-acetate.

• Mataki 4: Pre-Clinical & GMP-Shirye-shiryen Karatun Mataki (Ci: 100/100) - IND mai ba da damar nazarin toxicology, ci gaban rigakafin neoantigen, warkewa peptide gubar scaling na bukatar Class 100 sarrafa ɗaki mai tsabta da cikakken Fayil Jagorar Drug (DMF) goyon baya.

4. Takaddun Takaddun Ƙididdiga Na Nazari (CQS)

The Takaddun Takaddun Ƙididdiga Na Nazari (CQS) yana bincikar ɗanyen takaddun gwaji na mai kaya. Littattafan wallafe-wallafe suna tabbatar da aikin tarihi, amma bayanan matakin-CoA yana tabbatar da amincin jigilar kayayyaki nan da nan.

Kamar yadda aka rubuta a cikin Matsayin Magana na PMC don Peptides na roba (2023), Halayen nazari na peptides na roba dole ne ya tabbatar da ainihin jerin abubuwan farko, monoisotopic kwayoyin nauyi, tsarki kashi, da sauran ƙazanta masu alaƙa da tsari.

Don cimma nasarar CQS > 90, takaddun dillalai dole ne su bayar: Samuwar Peptide

1. Raw RP-HPLC Chromatograms: Cikakkun allunan haɗin kai suna nuna ƙimar yanki mafi girma, lokutan riƙewa, da ƙudurin tushe-ba kawai taƙaitaccen tsaftar lamba ɗaya ba.

2. Babban Haɗin Mass Spectrometry (HRMS): ESI-TOF ko MALDI-TOF spectra mai tabbatar da taro mai kauri da kuma nuna rashin tsarin sharewa., gutsuttsura, ko rashin cikar cire ƙungiyar kariya (misali, +100 Da Pbf).

3. Counterion Audit & Tabbatar da Musanya Gishiri: Tabbatacce bayyanannen nau'in gishiri (TFA, acetate, ko hydrochloride). Domin nazarin tantanin halitta da dabba, ragowar TFA dole ne a ƙididdigewa ko musanya zuwa acetate/hydrochloride don hana ƙwayar ƙwayar ƙwayar ƙwayar cuta.

4. Endotoxin & Gwajin Bioburden: Gwajin gwajin endotoxin na LAL mai ƙima (an ruwaito a cikin EU/mg, dacewa <0.05 EU/mg don al'adun sel da mai rai aiki) da kuma tabbatar da haihuwa.

Protocol mataki-mataki: Fassarar Littattafai don Ƙididdigar Reagent Mai Talla

Don aiki da wannan ƙirar ƙididdiga, sayayya da R&Ƙungiyoyin D za su iya bin ƙa'idar nazarin wallafe-wallafen matakai 4 da aka tsara a yayin binciken cancantar masu kaya..

Mataki 1: Binciken Corpus Na atomatik (PubMed/PMC madaidaicin kirtani)

Mataki 2: Hanyoyi Sashe Cire & Yin nazari (Regex / tushen doka) Mataki 3: Ƙididdigar Ƙididdigar Ƙirar Ƙididdigar Ƙirar Ƙira (Yi lissafin PCS, MRI, AAI) Mataki 4: Tabbatar da CoA na Analytical Cross-Validation (Daidaita wallafe-wallafe don batch CoA)

Mataki 1: Binciken Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwaƙwalwa na Ƙadda )

Fara da tambayar manyan bayanan adabi (PubMed Central, Masanin Google, Turai PMC) ta amfani da madaidaitan igiyoyin bincike na Boolean waɗanda ke haɗa sunan doka na mai siyarwa, alamar laƙabi, da sharuddan kira na al'ada tare da nomenclature peptide sunadarai.

("Supplier Legal Name" OR "Supplier Alias") AND ("custom peptide synthesis" OR "solid-phase peptide synthesis" OR "Fmoc synthesis") AND ("HPLC" OR "mass spectrometry" OR "purification")

Tace sakamakon bincike don ware abubuwan bincike na farko da aka yi bita da su yayin ban da takaddun bita, aikace-aikacen haƙƙin mallaka, da kasidu na kasuwanci.

Mataki 2: Ciro da Fasa Sashen Hanyoyi

Duba sashin gwaji na takaddun da aka ciro-musamman ƙananan sassan da aka yiwa lakabin "Reagents", "Peptide Synthesis", “Tsarin Ƙarfafan Halitta”, ko "Al'adun Kwayoyin Halitta".

Bincika rubutun hanyoyin don takamaiman alamun rahoto:

• Kalmomin Kalmomin Mai bayarwa: Nemo kalmomi marasa ma'ana kamar “haɓaka-haɗa ta [Sunan mai siyarwa], tsarki >98% kamar yadda RP-HPLC ta ƙaddara".

• Tsare-tsare da Tsari: Bincika idan takardar ta bayyana cikakken jerin amino acid ta amfani da daidaitattun lambobin haruffa 1 ko 3, ciki har da amino acid marasa canonical ko gadojin disulfide na cyclic.

• Haihuwar Gwaji: A cewar hukumar Ka'idojin Halitta Jagororin SPPS (2007), cikakken bayanin goyon bayan guduro, hada guda biyu reagents (misali, MATAKI, DIC/Oxyma), cleavage cocktails, kuma yanayin tsarkakewa na nazari suna da mahimmanci don tabbatar da ka'idojin haɗin peptide.

Mataki 3: Ƙididdiga Ma'auni

Shigar da bayanan da aka fitar a cikin matrix na mai siyar da ku na ciki. Yi lissafin PCS, MRI, da AAI don kowane ɗan takarar mai ba da kayayyaki bisa ga samfurin wakilci na 10-20 wallafe-wallafen kwanan nan.

Don Tukwici: Idan mai sayarwa ya yi iƙirarin ƙwarewar biopharma mai yawa amma yana nuna ƙimar MRI a ƙasa 40 saboda m hanyoyin sashe bayyanawa, nema 3 CoAs na abokin ciniki wanda ba a san shi ba don tabbatar da ko ƙarfin nazarin su ya dace da da'awar tallan su.

Mataki 4: Ƙididdigar Littattafan Giciye tare da Takamaiman CoA Data

Matakin ƙarshe na binciken ya haɗa da'awar wallafe-wallafe kai tsaye zuwa takaddun masana'anta na yanzu.

Nemi ƙayyadaddun CoAs na musamman don oda na baya-bayan nan ko jigilar samfurin batches daga masu siyar da takara. Kwatanta hanyoyin nazarin da aka ambata a cikin takardunsu da aka buga tare da danyen chromatogram da aka bayar a cikin CoAs nasu.:

• Yi matakan shafi, mobile zamani gradients (misali, Ruwa / Acetonitrile tare da 0.1% TFA), da tsinkayar raƙuman ruwa (214 nm / 220 nm) daidaita daidaitattun ƙa'idodin ƙa'idar nazari?

• Ana gabatar da bakan gizo-gizo tare da bayyanannun taro-zuwa caji (m/z) ambulan ayyuka don ninka caje ions ([M+H]^+, [M+2H]^{2+}, [M+3H]^{3+})?

Matrix Nazarin Harka: Ana kimantawa 3 Bayanan Bayanan Bayani na Mai siyarwa na yau da kullun

Don kwatanta yadda wannan tsarin ƙididdigan ke aiki a aikace, Yi la'akari da masu samar da peptide 'yan takara guda uku da ƙungiyar biopharma mai matsakaicin girman ta kimanta ta hanyar samar da ƙalubalen al'ada 35-mer cyclic peptide mai ƙunshe da haɗin haɗin intramolecular disulfide biyu da yanki mai matuƙar hydrophobic N-terminal don shirin inganta jagorar oncology..

Bayanan Nazari daga Matrix Nazarin Harka

• Bayanin A ya bayyana rinjaye lokacin duban ƙwaƙƙwaran ƙidayar ɗaba'ar (1,200+ takardu). Duk da haka, low MRI (42) da matsakaicin CQS (65) bayyana cewa wallafe-wallafen sun ƙunshi da farko masu sauƙi, ƙasidar ƙasidar ƙarancin tsarki. Lokacin ƙalubalanci tare da hadaddun cyclic 35-mer peptides, Profile A yana ɗauke da babban haɗari na nadawa mara kyau, tarawa, ko bambancin yawan amfanin ƙasa-zuwa-tsari.

• Bayanan martaba B ya gaza a duk ma'aunin ƙididdiga. Duk da tallan ƙananan farashi, Rashin hanyoyin sa sashe mai tsauri da rashin tantance takaddun CoA yana sigina rashin kulawar inganci da yuwuwar bambancin tsari-zuwa-tsari..

• Bayanan martaba C (misalta su ta hanyar dandamali masu ƙarfi kamar su MOL Yana Canza dandamalin haɗin peptide na al'ada) ya samu fitaccen VCS na 93.25. Ko da yake gabaɗayan ƙididdige ɗimbin ɗab'ar sa ya yi ƙasa da na Profile A, Sawun wallafe-wallafensa ya tattara sosai a cikin mujallolin biopharma masu tasiri. Bugu da kari, rikodinta da aka buga yana nuna ingantacciyar ƙwarewa a cikin mai wahala na nadawa jeri na 35-mer, cikakken TFA-to-acetate gishiri musayar, da Class 100 matsananci-bakararre aiki, sanya shi kyakkyawan abokin tarayya don haɓakar gubar biopharmaceutical mai girma.

Haɗa Ma'aunin Ƙididdigar Magana cikin Biopharma RFP & Audit Workflows

Sayi da kuma R&Ƙungiyoyin D za su iya shigar da wannan tsarin ƙididdigewa kai tsaye zuwa daidaitaccen tushen su da Buƙatun Ba da shawara. (RFP) hanyoyin.

⚠️ Gargadi: Kar a taɓa dogara da ƙasidan tallace-tallace na mai kaya ko bene na tallace-tallace a matsayin tabbacin iyawar nazari. Bukatar dillalai don gabatar da danyen, RP-HPLC chromatograms da ba a gyara ba da bakan HRMS don tsayin jeri da nau'ikan gyare-gyare masu kwatankwacin aikin da kuka yi niyya..

Lissafin Sayi Mai Aiwatarwa

Kafin bayar da odar siyayya ko sanya hannu kan yarjejeniyar babban sabis (MSA) don al'ada peptide kira, tabbatar da ma'auni na dubawa masu zuwa:

1. Binciken Binciken Adabi: Tabbatar cewa masu siyarwar ɗan takara zasu iya bayarwa aƙalla 5 wallafe-wallafen da aka yi bita a cikin na ƙarshe 36 watanni masu nuna nasarar haɗin peptides tare da tsayin tsayin jeri, hydrophobicities, ko hadaddun gyare-gyare (misali, Multi-disulfide gada, phosphorylated sharan gona, isotope labeling).

2. Hanyoyi Sashen Bayyana Gaskiya: Tabbatar da cewa ambaton abubuwan da aka buga a sarari suna ba da lambobi batch lot da cikakkun bayanan sifa na RP-HPLC/MS.

3. Wurin tsafta & Tabbatar da Haihuwa: Don al'adun tantanin halitta, Injiniyan nama, ko mai rai aikace-aikace, tabbatar da mai siyarwa yana aiki da ingantattun wuraren tsaftataccen ɗaki. Misali, samarwa cikin a Class 100 muhallin haɗaɗɗiyar ɗaki mai tsafta mara ƙarfi yana kawar da ƙananan ƙwayoyin cuta da haɗarin gurɓatawar endotoxin yayin haɗuwa da marufi.

4. Ladabar Tabbatar da CoA: Ana buƙatar ƙaddamarwa na CoA kafin jigilar kaya mai ɗauke da ɗanyen teburin haɗin kai na HPLC, monoisotopic taro tabbatarwa, net peptide abun ciki bincike, da kuma bayyani na lissafin gishiri (TFA vs. acetate vs. HCl).

5. Scalability da Daidaita CDMO: Tabbatar da hanyoyin gano farkon ganowa (milligram sikelin) na iya canzawa ba tare da wata matsala ba zuwa aiwatar da haɓakawa (gram zuwa kilogiram ma'auni) ba tare da musanya bayanan ƙazanta ko sunadarai na tsarkakewa ba. Kamar yadda aka ambata a cikin Farashin ACS OPR&D Ra'ayin Masana'antu akan Peptides na roba (2025), farkon zaɓi na scalable hada guda biyu reagents, kore ƙarfi tsarin, kuma ingantattun hanyoyin tsarkakewa suna hana sake tabbatar da tsari mai tsada yayin ci gaban asibiti daga baya.

Tambayoyin da ake yawan yi (FAQ)

Ta yaya sayayya zai iya bambanta tsakanin ƙididdiga na gaskiya da sake sanya alamar mai rarrabawa?

Masu rarrabawa sukan jera wallafe-wallafen inda aka sake tattara peptides a ƙarƙashin sunan alamar su ba tare da bayyana ainihin mai yin kwangila ba.. Don gano alamar mai rarraba farar alamar sake yin alama, duba ko sassan gwaji da aka buga sun faɗi takamaiman sigogin haɗawa (misali, samfurin synthesizer mai sarrafa kansa, guduro loading rates, cleavage cocktails). Masana'antun haɗin kai na asali yawanci suna ba da cikakkun takaddun fasaha, yayin da masu sake-sayarwa suka dogara da ambaton lambar samfur.

Me zai faru idan ƙwararren mai siyarwa yana da ƙarancin jimlar ƙididdiga saboda tsananin ƙuntatawar biopharma NDA?

CDMOs na kasuwanci da ƙwararrun masu samar da biopharma akai-akai suna aiki ƙarƙashin tsauraran yarjejeniyoyin rashin bayyanawa (NDAs) wanda ya hana abokan ciniki bayyana sunayen masu siyarwa a cikin littattafan ilimi. A irin wadannan lokuta, auna ƴan takara ta hanyar amfani da ingantaccen ƙira: nauyi da Hanyoyi Rigor Index (MRI) kuma Makin ingancin CoA (CQS) a 40% kowanne, kuma musanya ma'aunin ƙididdige ɗaba'a tare da ingantattun binciken kwatancen abokin ciniki da kan-site ko duba kayan aikin kama-da-wane.

Menene mafi ƙarancin ƙimar MRI don a cikin nazarin warkewa na vivo?

Domin mai rai nazarin dabba ko IND mai ba da damar kimanta aminci, ya kamata ƙungiyoyi masu samar da kayan aiki su aiwatar da mafi ƙarancin ƙimar MRI 80/100 da makin CQS na 90/100. A wannan matakin, Abubuwan da aka buga da takaddun tsari dole ne su tabbatar da musanyar musanya a sarari (acetate ko HCl nau'in gishiri tare da ragowar TFA < 1.0%), matakan endotoxin da ke ƙasa 0.05 EU/mg, da RP-HPLC tsarki ≥ 98%.

Matakai na gaba: Haɓaka Ladabi na Siyan Peptide

Mayar da sawun wallafe-wallafe da hanyoyin ƙididdiga zuwa ma'auni na ƙididdigewa yana ba da siyan biopharma da R.&D jagororin fa'ida mai mahimmanci. Maimakon dogaro da da'awar tallace-tallace da ba a tantance ba ko yaƙe-yaƙe na farashin-miligram, ƙungiyoyi za su iya zaɓar abokan haɗin gwiwar peptide bisa ga ƙwaƙƙwaran shaidar kimiyya, batch traceability, da tabbatar da tsantsar nazari.

Ko kuna tsara ɗakunan karatu na peptide masu rikitarwa, scaling hydrophobic jerin, ko shirya kayan don kimantawa kafin asibiti, haɗin gwiwa tare da ƙwararrun ƙira da aka kafa yana tabbatar da aiwatar da aikin maras kyau.

Don tattauna buƙatun ku na al'ada, hadaddun dabarun gyarawa, ko Class 100 bakararre masana'antu bukatun tare da gogaggen peptide chemists, bincika da MOL Yana Canza dandamalin haɗin peptide na al'ada da kuma buƙatar cikakken ƙima na yuwuwar fasaha a yau.